Yahoo
NasdaqCM - Nasdaq Real Time Price USD

Unicycive Therapeutics, Inc. (UNCY)

5.58 +0.30 (+5.68%)
As of 11:58:53 AM EDT. Market Open.
Trade UNCY on Coinbase
Chart Range Bar
Loading chart for UNCY
  • Previous Close 5.28
  • Open 5.30
  • Bid 4.03 x 100
  • Ask 6.87 x 100
  • Day's Range 5.10 - 5.70
  • 52 Week Range 3.71 - 8.74
  • Volume 1,757,470
  • Avg. Volume 1,315,990
  • Market Cap (intraday) 152.853M
  • Beta (5Y Monthly) 1.73
  • PE Ratio (TTM) --
  • EPS (TTM) -2.25
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 40.66

Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease. The company was incorporated in 2016 and is headquartered in Mountain View, California.

unicycive.com

21

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 7/2/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

UNCY
3.29%
S&P 500 (^GSPC)
9.19%

1-Year Return

UNCY
20.26%
S&P 500 (^GSPC)
20.02%

3-Year Return

UNCY
56.41%
S&P 500 (^GSPC)
67.95%

5-Year Return

UNCY
88.84%
S&P 500 (^GSPC)
71.73%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q4 FY25
Revenue --
Earnings -14.67M

Q1

FY25

Q2

FY25

Q3

FY25

Q4

FY25

-10M
-5M
0

Analyst Insights

View More

Analyst Price Targets

13.00
40.66 Average
5.58 Current
90.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 7/1/2026
Analyst Benchmark
Rating Action Maintains
Rating Speculative Buy
Price Action Lowers
Price Target 18 -> 13

Statistics

View More

Valuation Measures

Annual
As of 7/1/2026
  • Market Cap

    144.64M

  • Enterprise Value

    90.99M

  • Trailing P/E

    --

  • Forward P/E

    3.44

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    3.84

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -40.56%

  • Return on Equity (ttm)

    -163.14%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -39.89M

  • Diluted EPS (ttm)

    -2.25

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    54.59M

  • Total Debt/Equity (mrq)

    2.16%

  • Levered Free Cash Flow (ttm)

    -6.92M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

5.58 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: